The insurance industry has to be educated about what ReActiv8 means in terms of opportunities for chronic low back pain patients.
In this episode, Chip Moebus, Vice President of Reimbursement and Market Access at Mainstay Medical, talks about the Reactiv8 therapy and the different elements that play into bringing access to these types of innovations for chronic low back pain patients; The evidence generation and patient selection criteria, the groundwork necessary to educate the payer community, what makes ReActiv8 disruptive in the field, and its economic value. Mainstay Medical’s therapy has proven durability and opioid-usage reduction results in patients.
Tune in to learn about Chip's work to drive payer coverage, acceptance, and understanding of ReActiv8, a new solution for chronic low back pain!
Click this link to the show notes, transcript, and resources: outcomesrocket.health
Outcomes Rocket